find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
43
Clinical Trials
Multiple Myeloma
Phase I/II
Enrolling
nct/study# NCT06988488 / CA057-1040
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT06121843 / CA088-1005
A Phase 1, Open-Label Study that will test BMS-986393 in combination with 3 dual agent combinations of BMS-986393 (a chimeric antigen receptor CAR T-cell) with investigational treatments {Alnuctamab, Mezigdomide or Iberdomide} for safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics.
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / CAR-T-CELL-RRMM
CAR-T Cell Therapy Outcomes in Relapsed/Refractory Multiple Myeloma: A Retrospective Analysis Myeloma: A Retrospective Analysis
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# NCT05332054 / CARIBOU-LTFS
An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / CART-APHERESIS-OUTCOMES
Real World Outcomes of Patients who underwent apheresis for CAR-T
Learn More
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT05722418 / CB11A
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.